-
Product Insights
New![]()
Net Present Value Model: Biogen Inc’s Cirara
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Biogen Inc’s Litifilimab
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Biogen Inc’s Tofersen Sodium
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Biogen Inc’s BIIB-061
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Biogen Inc’s SAGE-324
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Biogen Inc’s Dapirolizumab pegol
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Biogen Inc’s DNL-151
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Biogen Inc’s BIIB-080
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Biogen Inc’s Aflibercept biosimilar
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Profile
![]()
Vascular Biogenics Ltd – Company Profile
Vascular Biogenics Ltd (Vascular Biogenics), dba VBL Therapeutics, operates as a provider of biopharmaceutical products. The company discovers, develops and commercializes gene-therapy medicines for the treatment of cancer and inflammatory diseases. Its lead product candidate VB-111, a gene-based biologic agent is developed to treat recurrent glioblastoma, colon, ovarian, thyroid cancer and solid tumors. Its pipeline products include VB 201 and VB 703, oral small molecules being developed through lecinoxoids platform for treating cardiovascular diseases, liver and renal fibrosis. Vascular Biogenics...
Add to Basket -
Product Insights
Chugai Pharma – Ukima Biogenic Drug Manufacturing Building – Tokyo
Equip yourself with the essential tools needed to make informed and profitable decisions with our Chugai Pharma - Ukima Biogenic Drug Manufacturing Building - Tokyo report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Company Profile
![]()
Biogen Inc – Company Profile
Biogen Inc (Biogen) is a biopharmaceutical company that discovers, develops, and delivers drugs and biosimilars for the treatment of various neurological and neurodegenerative diseases. The company’s marketed products include Avonex (interferon beta-1a), Vumerity (diroximel fumarate), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Fampyra (prolonged-release fampridine tablets), and Plegridy (peginterferon beta-1a) for the treatment of multiple sclerosis (MS), Spinraza (nusinersen) for spinal muscular atrophy (SMA), Aduhelm (aducanumab-avwa) for alzheimer’s disease, and Fumaderm (fumaric acid esters) for severe plaque psoriasis. It has several product...
Add to Basket -
Product Insights
New![]()
Net Present Value Model: AbbVie Inc’s ABBVRGX-314
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Alaunos Therapeutics Inc’s Gene-Modified Cell Therapy to Target CD56 for Oncology
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BIIB-091 in Relapsing Remitting Multiple Sclerosis (RRMS)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BIIB-091 in Relapsing Remitting Multiple Sclerosis (RRMS) Drug Details: BIIB-091 is under development for the treatment...
-
Product Insights
Biogenes Technologies Sdn Bhd Pipeline Insight and Competitive Landscape, 2023
Biogenes Technologies Sdn Bhd (Biogenes Technologies) develops and commercializes molecular diagnostics and genome solutions. Its product range includes DNA (Deoxyribonucleic acid), Aptamers and diagnostic kits; printed sensors; nano-coated sensor strips, covid-19 and other aptamers. The company utilizes its electronic portable reader technology to develop portable diagnostic devices; and in-silico design and validation platform technology to design aptamers. Its products find application in the areas of human and animal health, agriculture, food safety and environmental monitoring. The company collaborates with research...
-
Product Insights
New![]()
Net Present Value Model: RegenxBio Inc’s RGX-111
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. RegenxBio Inc's RGX-111 Drug Details: RGX-111 is under development for the treatment of children and adult subjects with Mucopolysaccharidosis Type I (MPS I)....
-
Product Insights
Giant Biogene Holding Co Ltd Pipeline Insight and Competitive Landscape, 2023
Giant Biogene Holding Co Ltd (Giant Biogene) is a biotechnology manufacturer company which serves in the fields of preventive medicine and nutritional medicine and dermatology. Giant Biogene is headquartered in Shaanxi, China. GlobalData's Medical Devices company profile report, “Giant Biogene Holding Co Ltd Pipeline Insight and Competitive Landscape, 2023" provides information about the company overview and analysis on their pipeline products. This company profile report provides key information and data related to: Top level information about the company performance and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BIIB-115 in Spinal Muscular Atrophy (SMA)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BIIB-115 in Spinal Muscular Atrophy (SMA) Drug Details: BIIB-115 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BIIB-113 in Alzheimer’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BIIB-113 in Alzheimer's Disease Drug Details:BIIB-113 is under development for the treatment of Alzheimer's disease. It...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.